Celgene says ABRAXANE combo treatment reduces CA19-9 levels

Celgene International Sàrl, a subsidiary of Celgene, announced several analyses of a phase III clinical trial of ABRAXANE in combination with gemcitabine in previously untreated patients with advanced pancreatic cancer. The data were presented at the American Society of Clinical Oncology 2013 annual meeting in Chicago. The MPACT overall trial results demonstrated that patients treated with ABRAXANE plus gemcitabine had a statistically significant improvement in overall survival compared with those treated with gemcitabine alone, as initially presented at an oral session at ASCO GI in San Francisco on January 25. In a June 3 oral session at ASCO, these overall survival results were presented, as well as data from additional exploratory efficacy endpoints. Data suggest treatment with ABRAXANE plus gemcitabine reduces levels of CA19-9 and increases the frequency of PET responses and both tools were found to be potential prognostic factors of overall survival, the company said.